

Achieving Remission in Treatment-Resistant Depression: Current Evidence and Research on Rapid-Acting Antidepressants

Industry session financially supported by GH Research during the 39th ECNP Congress.

🕒 **Saturday 10 October 2026**
13:20 – 14:40
📍 **Room 14b**

Programme Outline

Join us as we discuss the use of rapid-acting antidepressants as a treatment strategy for treatment-resistant depression (TRD), exploring the evidence for achieving rapid and sustained remission across approved and emerging pharmacological classes. Expert faculty will address efficacy, durability of effect, and practical integration into clinical practice, closing with an interactive panel discussion.

Session ID: ISS01
Session type: Industry Satellite Symposium

Faculty



CHAIRPERSON

Roger S. McIntyre

Professor of Psychiatry and Pharmacology, University of Toronto, Toronto, Canada.



SPEAKER

Bernhard T. Baune

Professorial Chair of Psychiatry, Head of the Department of Psychiatry, University of Münster, Münster, Germany



SPEAKER

Michael E. Thase

Professor of Psychiatry, Department of Psychiatry of the Perelman School of Medicine, University of Pennsylvania, Corporal Michael J. Crescenzi Veterans Affairs Medical Center, Philadelphia, U.S.A.



SPEAKER

Lisa Harding

Assistant Clinical Professor, Yale Department of Psychiatry, Medical Director, Mood Institute, Connecticut, U.S.A.

AGENDA

- **Welcome & Introduction**
Roger S. McIntyre
- **Rapid-Acting Antidepressants: From Phenomenology to Clinical Outcomes**
Bernhard T. Baune
- **Achieving Remission and Durability of Treatment Effect with Rapid-Acting Antidepressants**
Michael E. Thase
- **Rapid-Acting Antidepressants in Clinical Practice**
Lisa Harding
- **Panel Discussion**
All



Scan Or Click Here
For More Information